The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma
Authors:
- 1 May 2016
- journal article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 24 (5) , 355-363
Abstract
Osteosarcoma is the most common primary malignant bone tumor in Egypt. Ezrin is involved in cell adhesion to the extracellular matrix and in cell-cell interactions facilitating metastasis. HER2/neu is overexpressed in breast cancer and other types of cancer. This study aimed to assess the expression of ezrin and HER2/neu in 57 primary osteosarcoma cases and to correlate their expression with the available clinicopathologic parameters and the overall, metastasis-free and event-free survival. Both ezrin and HER2/neu were not expressed in the normal bone and they were upregulated in 82.5% and 71.9% of osteosarcoma, respectively. Positive ezrin expression was significantly associated with young age (below 25 y) (P=0.01), high grade (P=0.001), and short survival time (P=0.0001). Positive HER2/neu expression was significantly associated with high-grade osteosarcoma (P=0.04). Membranous HER2/neu expression was the only factor that showed significant impact on metastasis-free (P=0.002) and event-free survival (P=0.002). Ezrin was significantly correlated with HER2/neu expression (P=0.02). Advanced stage (P=0.0001), metastasis (P=0.0001), and recurrence (P=0.01) were the factors affecting the overall survival of osteosarcoma patients. Ezrin and HER2/neu are overexpressed and coexpressed in osteosarcoma with adverse prognostic features such as high grade. Membranous pattern of HER2/neu seems to be more important than the cytoplasmic pattern because of its impact on metastasis-free and event-free survival. Therefore, ezrin and HER2/neu could be potential prognostic markers and treatment targets for osteosarcoma.Keywords
This publication has 41 references indexed in Scilit:
- HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerBreast Cancer Research and Treatment, 2013
- The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published DataPLOS ONE, 2013
- Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal CancerClinical Medicine Insights: Oncology, 2013
- Ezrin overexpression predicts the poor prognosis of gastric adenocarcinomaDiagnostic Pathology, 2012
- Osteosarcoma in very young childrenCancer, 2010
- Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Clinical Value of Ezrin Expression in Primary OsteosarcomaCancer Research and Treatment, 2009
- Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathwayClinical & Experimental Metastasis, 2006
- Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomasBreast Cancer Research and Treatment, 2006
- Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomasEuropean Journal of Cancer, 2004